The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Broker Ratings Changes Drive FTSE 100 Movers

Mon, 23rd Mar 2015 11:22

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Monday.
-------
FTSE 100 WINNERS
-------
Standard Chartered, up 5.1%. JP Morgan has raised the emerging markets bank to Overweight from Neutral.
-------
FTSE 100 LOSERS
-------
Carnival, down 2.8%. Deutsche Bank has downgraded the cruise operator to Hold from Buy.

Meggitt, down 1.9%. Bernstein has downgraded the engineer of components for the aerospace, defence and energy markets to Market-Perform from Outperform, according to traders.
-------
FTSE 250 WINNERS
-------
Centamin, up 14%. The Egypt-focused gold miner reported a sharp drop in pretax profit for 2014 as the falling gold price offset a rise in production, but the company still declared a dividend for the year. Centamin said its pretax profit for the year was USD81.6 million, less than half the USD184 million it posted a year earlier. Revenue dropped to USD472.6 million from USD503.8 million. However, the company proposed a final dividend of 1.99 US cents per share, giving it a total payout of 2.86 cents per share for the year. Centamin paid no dividend in 2013.

FirstGroup, up 3.8%. The transport operator said it had retained the First Great Western rail franchise in the UK until at least April 2019, and pledged to add new and updated trains, faster services, more direct trains to Devon and Cornwall and improvements to infrastructure. The company said it will continue the franchise until April 1, 2019, and the deal could be extended for a further year at the UK government's discretion. It has already been running the franchise since 2006.

Vedanta Resources, up 2.4%. JP Morgan has raised the miner's price target to 520.00 pence from 450.00p. The stock currently trades at 537.50p.

Pennon Group, up 1.8%. The water utility and waste management company said trading remains in line with expectations for its financial year to the end of March, with its South West Water business performing well and its Viridor waste management division making progress, leading the company to reiterate its dividend growth plans. It said it is well placed to generate increasing operating cashflows over the 2015-2020 regulatory period and, as a result, intends to continue with its current dividend policy of year-on-year growth of 4% above UK retail prices index inflation over that period.
-------
AIM ALL-SHARE WINNERS
-------
Silence Therapeutics, up 22%. The company said it had seen an "excellent outcome" in its Phase IIa trial of compound Atu027 in pancreatic cancer. The primary objective of the trial was to assess the safety and pharmacokinetics of the compound, and the second objective was to evaluate its efficacy including progression free survival.

Verona Pharma, up 21%. The company said it has seen "very encouraging" initial interim results from its ongoing phase I/II clinical trial with a new nebulised formulation of its RPL554 compound. Results from the first part of the study showed the drug was well tolerated across all doses tested, and no maximum tolerated dose could be defined. It noted that there were no changes in the subject's cardiovascular parameters, and a complete absence of nausea or vomiting at all doses.

Metal Tiger, up 19%. The company said it has now implemented its divisional restructuring and is in the position to self-finance its activities. The company said its two new investment divisions, Direct Equities and Direct Projects, are now embedded and fully operational. It had said in Late January it was to create the new structure as part of an updated strategic approach.

Premaitha Health, up 16%. The company said it has been awarded a three-year contract to provide its non-invasive prenatal test, known as IONA, to St George's University Hospitals NHS Foundation Trust. The test is currently the subject of a patent infringement suit filed by NASDAQ listed Illumina Inc last Monday. The contract was awarded following a competitive tender process, and St George's Hospital in South West London will be the first National Health Service facility to offer non-invasive prenatal testing in-house.
-------
AIM ALL-SHARE LOSERS
-------
Clean Air Power, off 31%. The company reported a sharp drop in revenue and an increase in cash consumption in 2014 and warned that 2015 would also be challenging as it seeks fresh funding to shore up an uncertain financial future. Clean Air Power said it faces significant doubt over whether it can continue in business unless it secures additional funding. It said it now has limited means to further cut costs, and is now seeking fresh funding through either a second major deal with a manufacturer, which would boost cash flow, or "alternative sources of funding". It said talks are ongoing with a number of manufacturers.

SpaceandPeople, down 15%. The marketing company said its pretax profit dropped in 2014 as a rise in its cost of sales outpaced revenue growth and said it would slash its dividend. It said its pretax profit fell to GBP596,000 from GBP1.8 million a year earlier.

Egdon Resources, down 10%. Europa Oil & Gas and Egdon Resources said they have plugged and abandoned the Kiln Lane-1 exploration well in the East Midlands of England and will return the site to farmland after drilling encountered sandstones with too much water.
-------

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
2 Mar 2018 15:01

BUZZ-Verona Pharma: Soars on positive data from mid-stage study

** British drug developer's U.S.-listed shares up 16 pct at $16.44 in morning trade - second highest gainer amongst Nasdaq-listed companies ** data a

Read more
18 Jan 2017 10:13

Verona Pharma Proposes Share Consolidation Amid Plans To List In US (ALLISS)

Read more
26 Sep 2016 09:39

Verona Pharma appoints sector veteran Morgan as CFO

(ShareCast News) - AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug. Chartered accountant Morgan has 25 years' financial experience and was previously c

Read more
13 Sep 2016 12:04

Verona Pharma makes progress on new respiratory drug

(ShareCast News) - Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554". The company's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulized maintenance tr

Read more
20 Jun 2016 15:02

UK Shareholder Meetings Calendar - Next 7 Days

Read more
20 Jun 2016 12:50

Verona Pharma secures funding for drug trial

(ShareCast News) - Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed. Net proceeds from the placing with new

Read more
20 Jun 2016 11:06

LONDON MARKET MIDDAY: Receding Brexit Fear Lifts Stocks And Pound

Read more
20 Jun 2016 09:40

WINNERS & LOSERS SUMMARY: Cat Allergy Disappointment Sinks Circassia

Read more
17 Jun 2016 16:09

Verona Pharma To Raise GBP44.7 Million In Share Placing (ALLIS)

Read more
3 Jun 2016 12:52

Verona Pharma's shares fall as higher R&D costs widen FY loss

(ShareCast News) - Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling. Chief executive Jan-Anders Karlsson said Verona had made substantial clinical progress with its

Read more
3 Jun 2016 06:59

Verona Pharma Loss Widens On Higher Research And Development Costs

Read more
10 May 2016 08:11

Verona Pharma Gets Positive Results From COPD Treatment Study

Read more
15 Mar 2016 10:35

Verona Pharma excites with asthma trial results

(ShareCast News) - Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD). Tests among asthma patients found the inhaled drug, which has both bronchodilator and anti-inflammatory properties in the same active molecu

Read more
21 Jan 2016 13:31

DIRECTOR DEALINGS: Verona Pharma Chairman Ups Interest

Read more
11 Jan 2016 08:45

Verona Pharma Chief Financial Officer Biresh Roy Leaving Company

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.